Clinical Nurse Specialist Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Robin Potter-Kimball

Clinical Nurse Specialist, Psychiatric/Mental Health Oklahoma City, OK Clinical Nurse Specialist

NPI 1841399904 CMS profile 11185744

3208 Nw 63Rd Street, Oklahoma City, OK 73116

Open in the dashboard

General payments

$6,223

270 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robin Potter-Kimball of Oklahoma City, OK is reported in the CMS Open Payments database as having received $6,223 across 270 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Clinical Nurse Specialist, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,456 70
2024 General $1,653 67
2023 General $1,964 73
2022 General $1,150 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robin Potter-Kimball
  • Clinical Nurse Specialist, Psychiatric/Mental Health median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Robin Potter-Kimball were reported at $1,456. Among 300 Clinical Nurse Specialist, Psychiatric/Mental Health profiles paid that year, the median was $245 and the middle half received between $78 and $929.

Show as a table
Year Robin Potter-Kimball Clinical Nurse Specialist, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $153 $44–$540 $132
2022 $1,150 $207 $60–$748 $149
2023 $1,964 $197 $55–$898 $160
2024 $1,653 $189 $49–$804 $164
2025 $1,456 $245 $78–$929 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Otsuka America Pharmaceutical, Inc. $1,553 67 payments
  2. ITI, Inc. $1,112 41 payments
  3. AbbVie, Inc. $774 54 payments
  4. Axsome Therapeutics, Inc. $741 33 payments
  5. Janssen Pharmaceuticals, Inc $667 19 payments
  6. Neurocrine Biosciences, Inc. $456 14 payments
  7. Alkermes, Inc. $396 12 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $195 11 payments
  9. Lundbeck LLC $164 9 payments
  10. E.R. Squibb & Sons, L.L.C. $54 3 payments
  11. Other $112 7 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $6,215 269 payments
  2. Education $8 1 payment
Products named General payments · program years 2022–2025
  1. REXULTI $1,312 62 payments
  2. CAPLYTA $1,082 39 payments
  3. Auvelity $741 33 payments
  4. VRAYLAR $612 40 payments
  5. SPRAVATO $529 18 payments
  6. ABILIFY MAINTENA $431 20 payments
  7. LYBALVI Cns $396 12 payments
  8. LYBALVI Cns $332 9 payments
  9. LYBALVI Cns $315 8 payments
  10. LYBALVI Cns $315 8 payments
  11. Other $1,552 83 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,101

Median for Certified Clinical Nurse Specialist: 344

Drug cost

$108,302

Median for Certified Clinical Nurse Specialist: $20,739

Branded share of claims

25.2%

Median for Certified Clinical Nurse Specialist: 20.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 14 $41,118
Trintellix Vortioxetine Hydrobromide Brand 45 $21,367
Lamictal Lamotrigine Brand 15 $16,171
Lurasidone Hcl Generic 42 $6,576
Belsomra Suvorexant Brand 11 $5,479
Duloxetine Hcl Generic 101 $2,255
Bupropion Xl Bupropion Hcl Brand 122 $2,107
Vilazodone Hcl Generic 17 $1,630
Aripiprazole Generic 60 $1,525
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 16 $1,064

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,644 Part D prescribers listed as Certified Clinical Nurse Specialist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$21,155

Medicare's payments for the services billed

Medicare patients

54

Average age 72

Services billed

540

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 67%
High blood pressure 65%
Depression 63%
Diabetes 28%
COPD 22%
Osteoporosis 22%
Ischemic heart disease 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $351
  • Lundbeck LLC $34
  • Otsuka Pharmaceutical Development & Commercialization, Inc. $23
$408 — —
CAPLYTA
  • ITI, Inc. $296
$296 — —
Auvelity
  • Axsome Therapeutics, Inc. $293
$293 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $202
$202 — —
VRAYLAR
  • AbbVie, Inc. $173
$173 14 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

270 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record